Clinical stage biopharmaceutical company Acticor Biotech (Euronext Growth: ALACT) announced on Tuesday that it has successfully concluded patient recruitment for its ACTISAVE Phase 2/3 clinical trial.

The study, spanning the US, Europe, Israel and the UK, evaluated glenzocimab's safety and efficacy in treating acute ischemic stroke. The trial enrolled 438 patients, with results anticipated in Q2 2024.

Acticor Biotech plans to consult with regulatory authorities in 2024 to confirm Phase 3 design alignment for final registration in Europe and the United States by 2028.

The company is a spin-off from INSERM and focuses on developing innovative treatments for cardiovascular emergencies, particularly ischemic stroke. Its Phase 1b/2a study, ACTIMIS, demonstrated the safety of glenzocimab and exhibited reduced mortality and intracerebral haemorrhage in treated stroke patients. Acticor Biotech holds 'PRIME' status from the European Medicines Agency for glenzocimab in stroke treatment.